Listening to stories from leaders in the field of MS, and discovering innovative ideas at ECTRIMS, can inspire you in your own clinical and research practice, so you can bring home something valuable and significant. So, overall, if you want to keep up with the latest trends and breakthroughs in the rapidly evolving field of MS, you better, join us at MSMilan2023.
2023 has been an exciting year for new technologies such as artificial intelligence. In my talk, I'm going to speak about the new aspects of such technologies that might be used in clinical research for multiple sclerosis patients and how this may revolutionise the way we understand and treat MS.
We know that we have a huge therapeutical landscape for MS with an increasing number of eye efficacy treatments. These later drugs have a greater efficacy but also higher risk, mainly for infections. During my presentation, I will talk about the importance of adopting risk mitigation strategies in order to reduce these risks.
At the upcoming MSMilan2023 conference, I will be discussing principles of one of the two general approaches to treatment of multiple sclerosis, and that is the strategy of treatment escalation. I will be providing an overview of some of the evidence around treatment initiation, the rules for sequencing and the limitations of this approach.
The insights that I'm going to be sharing with all of you have to do with our latest work in the genetics of MS severity. I will be presenting our latest genetic association study that discovered a new genetic variant associated with disease severity.
I will comment on infectious and somatic diseases, as well as how conditions associated to long-term use of medications can affect the severity of multiple sclerosis as it progresses. The aim of our work is to study the influence of cerebrovascular diseases on the cause of MS.
A clear understanding of regional conditions and comorbidity prevalence in established MS populations is needed. Therefore, understanding these risk factors for developing such diseases and how this might affect MS progression is critical for individualised treatment that could improve outcomes of persons with MS.
EBV infects more than 95% of the human adult population and can cause during primary infection some of the strongest T cell activations and expansions known in man. These manifest in infectious mononucleosis and increase the risk to develop multiple sclerosis. In my presentation at the ECTRIMS meeting in Milan, I will describe the phenotype of T cells that are expanded by EBV and its characteristics that protect most virus carriers from associated disease.
Every year ECTRIMS is the biggest conference in our field. It might seem that it's just a European conference, but that is actually not the case. The entire world is looking at ECTRIMS every year for the latest insights into MS research, new developments for treatment, new mechanisms underlying symptoms and different ways of studying what causes MS and how we could slow it down. Every year this is the biggest one, and this year in Milan is going to be amazing.